@article {RAMI{\'C}2509, author = {SNJE{\v Z}ANA RAMI{\'C} and KSENIJA ASI{\'C} and MELITA PERI{\'C} BALJA and FRANE PAI{\'C} and VESNA BENKOVI{\'C} and FABIJAN KNE{\v Z}EVI{\'C}}, title = {Correlation of Phosphorylated HER2 with Clinicopathological Characteristics and Efficacy of Trastuzumab Treatment for Breast Cancer}, volume = {33}, number = {6}, pages = {2509--2515}, year = {2013}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To determine the correlation of phosphorylated human epidermal growth factor receptor-2 (pHER2) with clinicopathological characteristics of breast cancer (BC) and patients{\textquoteright} response to trastuzumab-based therapy. Patients and Methods: pHER2 was determinated immuno-histochemically in 88 cases of HER2-positive and 50 cases of HER2-negative BC. All patients with HER2-positive BC received trastuzumab-based therapy and 16 of them (18.2\%) had disease progression during therapy treatment (i.e. trastuzumab-resistant). Results: pHER2 was predominantly expressed in HER2-positive BC, with 55 cases (62.5\%) of tumours expressing pHER2. Six cases of HER2-negative cancer (12.5\%) displayed positive expression of pHER2. Expression of pHER2 correlated with younger age of patients and negative oestrogen receptor status. Acquisition of resistance to trastuzumab correlated with negativity for pHER2 (p=0.028). Conclusion: Positive expression of pHER2 may yield additional information regarding the poor prognosis of BC and could be used for pre-selection of patients with HER2-overexpressing BC displaying resistance to trastuzumab treatment.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/33/6/2509}, eprint = {https://ar.iiarjournals.org/content/33/6/2509.full.pdf}, journal = {Anticancer Research} }